Training – Opioid Use Disorders
Courses on Office-Based Treatment of Opioid Use Disorders are presented at both the Annual Meeting and Institute on Psychiatric Services. Completion of the 8-hour course qualifies the physician to receive a waiver to treat opioid use disorder in an office-based setting. APA also offers an on-line buprenorphine training course that is accessible at www.APAeducation.org
Training – Buprenorphine
APA was a partner organization in the Physicians’ Clinical Support System for Buprenorphine (PCSS-B) and organized monthly webinars for physicians and other interested clinicians. Though the program ended in May 2013, recordings of each of the webinars remain accessible on APA’s website (www.psychiatry.org\buprenorphinewebinars)
Training – Opioid Therapies
APA is a partner organization in the Providers’ Clinical Support System for Opioid Therapies (PCSS-O) and presents occasional webinars on topics related to the appropriate use of opioids in the treatment of chronic pain and recognition and treatment of opioid use disorder. APA-sponsored webinars are accessible at www.psychiatry.org\pcssowebinars. Resources provided by all of the partner organizations in the PCSS-O are accessible at www.pcss-o.org
Training – Medication Assisted Treatment
APA is a partner organization in the Providers’ Clinical Support System for Medication Assisted Treatment (PCSSMAT). This program expands on the former PCSS-B to include all FDA-approved medications for the treatment of opioid use disorders. APA’s contribution to the program is a series of 16 webinars per year. Live presentations are scheduled for the second Tuesday of each month at noon Eastern. Recordings are made available at www.APAeducation.org (with CME option) and at www.psychiatry.org\pcssmatwebinars (without a CME option). The programs dedicated website is www.pcssmat.org.
Recently approved Position Statements include Use of Medical Marijuana for posttraumatic Stress Disorder and Marijuana as Medicine. The council is also collaborating with the Council on Psychiatry and Law on a statement that addresses decriminalization of marijuana. It is expected to be approved in 2014.
Full list of Council Members 2013-2014
The Charge to APA’s Council on Addiction Psychiatry is:
• Providing psychiatric leadership in the growing field of prevention and treatment of addictive disorders;
• Developing and clarifying the role of the psychiatrist in the prevention and treatment of addictive disorders;
• Formulating policy recommendations related to prevention, education, treatment, and research in addictive disorders;
• Considering important developments in basic knowledge, treatment, methodology, treatment systems, and related matters in the field of addictive disorders, and dissemination of that knowledge;
• In cooperation with other appropriate APA components, enhancing the quality and quantity of medical education in addictive disorders, at all educational levels, including undergraduate, residency, fellowship, and continuing medical education;
• Providing additional liaison to medical, educational, consumer interest, and governmental organizations interested in alcohol and other drug problems;
• Collaborating with other councils and components of the APA on common issues related to the role of psychiatry in addictive disorders; for example, to improve the quality of care and risk management for addictive disorders, to foster adequate research efforts and funding, and to foster adequate reimbursement for treatment.
• Liaison with the American Academy of Addiction Psychiatry (AAAP) to address mutual interests and priorities and advance shared goals
Scope of work and work product:
The Council will:
(1) maintain active communication and collaboration with Federal agencies and offices (i.e., White House Office of National Drug Control Policy, National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism, Substances Abuse and Mental Health Services Administration and its Center for Substance Abuse Treatment);
(2) provide ongoing consultation to initiatives to train and provide clinical mentorship to physicians who treat opioid use disorders,
(3) consult with the Department of Government Relations on legislative and policy initiatives that impact education, research, and clinical care;
(4) maintain ongoing collaboration with components focused on other psychiatric subspecialties and seek opportunities to join together in efforts to strengthen the respective fields;
(5) work closely and collaboratively with the American Academy of Addiction Psychiatry.